RDEIY vs KRYS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RDEIY · REDEIA CORPORACION SA UNSP ADR EACH REPR 0.5 ORD$8.69 ▼ 1.14%
KRYS · Krystal Biotech$300.88 ▲ 0.21%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RDEIY +2.9%
- KRYS +50.8%
Head to head
| Metric | RDEIY | KRYS |
|---|---|---|
| Price | $8.69 | $300.88 |
| Change today | ▼ 1.14% | ▲ 0.21% |
| Market cap | $8.94B | $8.92B |
| Return, 3 months | -1.3% | -9.3% |
| Return, year to date | -2.2% | +22.0% |
| Return, 1 year | +2.9% | +52.0% |
| P/E (TTM) | 16.1 | 40.9 |
| P/B | 1.4 | 6.2 |
| P/E percentile vs own 5y | – | 69th |
| Dividend yield | 5.26% | – |
| Revenue growth (YoY, latest qtr) | – | +24.1% |
| Net profit growth (YoY) | – | +42.9% |
| Gross margin | – | 94.6% |
| Operating margin | – | 44.9% |
| Net margin | – | 54.8% |
| Return on equity | – | 20.1% |
| Analyst target vs. price | – | +34.1% |
| Analyst buy share | – | 88% |
| RSI (14) | 61 | 40 |
| 30-day volatility | 18.5% | 46.7% |
| Max drawdown, 1 year | -16.7% | -21.8% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RDEIY is the largest of the group by market value.
- KRYS has returned the most over the past year.
- RDEIY carries the lowest trailing P/E.
- RDEIY has been the calmest stock over the last 30 days.